QUICK REFERENCE

Steps to reduce emergency department visits and help your patient by combining withdrawal treatment with craving reduction:

1. **Treat Acute Withdrawal**
   - Use your preferred strategy/hospital standard practice with benzodiazepine and/or phenobarbital to treat acute withdrawal.

2. **At Discharge**
   - a. Prescribe Medication for protracted withdrawal.
      - Gabapentin 600mg-900 TID, #42
      - Avoid/use with caution in renal disease.
      - If history of severe withdrawal may need additional treatment including with benzodiazepines
   - b. Prescribe Medication to reduce craving and relapse.
      - Naltrexone 50mg PO Daily #14;
      - **Contraindications:**
        - Any opioid use—incl. planned surgery/anesthesia, buprenorphine starts, or OUD
        - Acute liver injury with LFTS > 5x normal
        - Decompensated cirrhosis

3. **Contact the SUN (Substance Use Navigator)**
   - The SUN will problem solve, motivate and arrange follow up care.

4. **At follow up**
   - Offer 30day Naltrexone injection (Vivitrol)
GUIDE

Acute Care Treatment of Alcohol Use Disorder

Eleven million Americans have an alcohol use disorder while two million Americans have an opioid use disorder. Screening, brief intervention, and referral to treatment is proven to decrease risky drinking and alcohol use disorder-related behaviors in acute care settings. Targeting patients presenting for trauma may be particularly effective.

This guidance is for hospitals participating in the California Bridge Program who would like to incorporate treatment for alcohol use disorder into their emergency departments and inpatient settings. This is part of the Practice Under Development series presenting information about practices we are piloting and continuing to refine. This guidance does not focus on withdrawal treatment, rather the focus here is on the initiation of medications to decrease cravings and acute care utilization.

Consider screening:

- Men < 65 yo: How many times in the past year have you had 5 or more drinks in a day?
- All women, men > 65: How many times in the past year have you had 4 or more drinks in a day?

Alcohol withdrawal management:

- Treat per the protocols of your facility
- Consider phenobarbital, benzodiazepines
- Consider gabapentin (ex: gabapentin 600 mg PO TID #42), caution in renal disease, if severe withdrawal may need additional treatment

Offer maintenance treatment:

- First line is naltrexone, which is FDA approved for AUD treatment:
  - Naltrexone PO:
    - E.g.: naltrexone 50 mg PO, 1 tab PO qday, dispense #14, 0 refills
  - Naltrexone IM:
    - Consider if patients unable to take daily medication, but have tolerated PO naltrexone
    - Naltrexone 380 mg IM x 1 in buttock monthly – consider at least one trial PO dose before injection
    - Covered by MediCal for outpatient treatment, pharmaceutical company may be able to provide acute care doses
  - Cautions and contraindications:
    - Avoid if patient has active OUD or opioid dependence or is on buprenorphine (recommend at least 7 days off of opioids if physically dependent)—can consider test dose of naloxone or PO naltrexone to ensure no withdrawal
    - Avoid if planned surgery or anesthesia needed
    - Avoid if AST and ALT >5x upper limit of normal or Childs Pugh class C
  - Adverse effects:
    - Headache, GI distress, opioid withdrawal, injection site reaction, transaminitis
- Second line: Multiple agents, select based on comorbidities and patient preference (see table below)
Discharge from acute care with direct linkage to ongoing treatment if possible in clinic, intensive outpatient program, medically assisted withdrawal (detox) facility, residential treatment as fits patient’s interest and program availability.

Consider the first dose of IM naltrexone in acute care for those who have not been able to successfully connect on prior presentations if possible.

Always contact your SUN who can work with the patient to motivate, make shared decisions, and ensure follow up.

<table>
<thead>
<tr>
<th>Target population</th>
<th>Efficacy</th>
<th>Contraindications/ADEs</th>
<th>Dosing</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Naltrexone (first line)</strong></td>
<td>First line for most people without contraindications</td>
<td>NNT 9 for return to heavy drinking</td>
<td>Opioid use (risk of withdrawal), planned surgery/anesthesia AST and ALT &gt;5x ULN ADEs: HA, GI distress, opioid w/d, injection site rnx, transaminitis</td>
</tr>
<tr>
<td><strong>Topiramate</strong></td>
<td>Consider if also using cocaine, PTSD, seizure hx, overweight</td>
<td>NNT 7.5 for return to heavy drinking 7.5</td>
<td>Dose reduce in CKD Cognitive slowing, weight loss, paresthesias, altered taste, metabolic acidosis Avoid if hx kidney stones, narrow-angle glaucoma</td>
</tr>
<tr>
<td><strong>Baclofen</strong></td>
<td>Consider if also chronic pain, liver disease</td>
<td>Not effective in meta-analyses</td>
<td>Dose reduce in CKD Somnolence, dizziness</td>
</tr>
<tr>
<td><strong>Gabapentin</strong></td>
<td>Consider if neuropathic pain, anxious, EtOH withdrawal Helps when added to naltrexone if naltrexone had some efficacy</td>
<td>Mixed evidence</td>
<td>Dose reduce in CKD Somnolence, dizziness, GI effects, HA Note, some abuse liability and can potentiate opioids</td>
</tr>
<tr>
<td><strong>Acamprosate (FDA approved)</strong></td>
<td>Patients who are already abstaining, prevents relapse, safe in liver disease</td>
<td>NNT 9 to reduce risk of any drinking</td>
<td>Causes diarrhea, fatigue, GI upset</td>
</tr>
<tr>
<td><strong>Disulfiram (FDA approved)</strong></td>
<td>Patients who are already abstaining, prevents relapse, only effective if observed dosing by family, opioid treatment program</td>
<td>If not directly observed, outcomes similar to placebo</td>
<td>Causes physical illness if return to use, do not start if ongoing EtOH use Causes metallic taste, hepatotoxicity, optic neuritis, peripheral neuropathy</td>
</tr>
<tr>
<td><strong>Varenicline</strong></td>
<td>Men who are also smokers</td>
<td>Decreased heavy drinking in male smokers</td>
<td>Dose reduce in CKD Caution in depression</td>
</tr>
</tbody>
</table>

GUIDE: Acute Care Treatment of Alcohol Use Disorder, November 2020

More resources available www.CAbridge.org
REFERENCES


